Literature DB >> 12671043

Heparan sulfate: antithrombotic or not?

Jeffrey I Weitz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12671043      PMCID： PMC152594          DOI： 10.1172/JCI18234

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  20 in total

1.  Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasis.

Authors:  Sassan HajMohammadi; Keiichi Enjyoji; Marc Princivalle; Patricia Christi; Miroslav Lech; David Beeler; Helen Rayburn; John J Schwartz; Samad Barzegar; Ariane I de Agostini; Mark J Post; Robert D Rosenberg; Nicholas W Shworak
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

Review 2.  The dynamics of thrombin formation.

Authors:  Kenneth G Mann; Saulius Butenas; Kathleen Brummel
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-01-01       Impact factor: 8.311

3.  Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis.

Authors:  B Isermann; S B Hendrickson; M Zogg; M Wing; M Cummiskey; Y Y Kisanuki; M Yanagisawa; H Weiler
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

4.  Structural requirements and mechanism for heparin-induced activation of a recombinant mouse mast cell tryptase, mouse mast cell protease-6: formation of active tryptase monomers in the presence of low molecular weight heparin.

Authors:  J Hallgren; D Spillmann; G Pejler
Journal:  J Biol Chem       Date:  2001-08-31       Impact factor: 5.157

5.  Complete antithrombin deficiency in mice results in embryonic lethality.

Authors:  K Ishiguro; T Kojima; K Kadomatsu; Y Nakayama; A Takagi; M Suzuki; N Takeda; M Ito; K Yamamoto; T Matsushita; K Kusugami; T Muramatsu; H Saito
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

6.  Life-threatening thrombosis in mice with targeted Arg48-to-Cys mutation of the heparin-binding domain of antithrombin.

Authors:  Mieke Dewerchin; Jean-Pascal Hérault; Goedele Wallays; Maurice Petitou; Paul Schaeffer; Laurence Millet; Jeffrey I Weitz; Lieve Moons; Désiré Collen; Peter Carmeliet; Jean-Marc Herbert
Journal:  Circ Res       Date:  2003-10-30       Impact factor: 17.367

7.  Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability.

Authors:  T Koide; S Odani; K Takahashi; T Ono; N Sakuragawa
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

8.  Contribution of 3-O- and 6-O-sulfated glucosamine residues in the heparin-induced conformational change in antithrombin III.

Authors:  D H Atha; J C Lormeau; M Petitou; R D Rosenberg; J Choay
Journal:  Biochemistry       Date:  1987-10-06       Impact factor: 3.162

9.  Homozygous variant of antithrombin III: AT III Fontainebleau.

Authors:  C Boyer; M Wolf; J Vedrenne; D Meyer; M J Larrieu
Journal:  Thromb Haemost       Date:  1986-08-20       Impact factor: 5.249

10.  Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan.

Authors:  J A Marcum; D H Atha; L M Fritze; P Nawroth; D Stern; R D Rosenberg
Journal:  J Biol Chem       Date:  1986-06-05       Impact factor: 5.157
View more
  9 in total

Review 1.  Intracellular proteoglycans.

Authors:  Svein Olav Kolset; Kristian Prydz; Gunnar Pejler
Journal:  Biochem J       Date:  2004-04-15       Impact factor: 3.857

2.  A Mathematical Model of Venous Thrombosis Initiation.

Authors:  Priscilla Elizondo; Aaron L Fogelson
Journal:  Biophys J       Date:  2016-12-20       Impact factor: 4.033

3.  Heparanase regulates thrombosis in vascular injury and stent-induced flow disturbance.

Authors:  Aaron B Baker; William J Gibson; Vijaya B Kolachalama; Mordechai Golomb; Laura Indolfi; Christopher Spruell; Eyal Zcharia; Israel Vlodavsky; Elazer R Edelman
Journal:  J Am Coll Cardiol       Date:  2012-04-24       Impact factor: 24.094

Review 4.  Heparin-binding domains in vascular biology.

Authors:  Eva M Muñoz; Robert J Linhardt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-07-01       Impact factor: 8.311

5.  Dynamic in vivo biocompatibility of angiogenic peptide amphiphile nanofibers.

Authors:  Shahram Ghanaati; Matthew J Webber; Ronald E Unger; Carina Orth; James F Hulvat; Sarah E Kiehna; Mike Barbeck; Angela Rasic; Samuel I Stupp; C James Kirkpatrick
Journal:  Biomaterials       Date:  2009-08-15       Impact factor: 12.479

6.  Growth Differentiation Factor 5-Mediated Enhancement of Chondrocyte Phenotype Is Inhibited by Heparin: Implications for the Use of Heparin in the Clinic and in Tissue Engineering Applications.

Authors:  Bethanie I Ayerst; Raymond A A Smith; Victor Nurcombe; Anthony J Day; Catherine L R Merry; Simon M Cool
Journal:  Tissue Eng Part A       Date:  2017-01-06       Impact factor: 3.845

Review 7.  Endothelial Glycocalyx Degradation in Critical Illness and Injury.

Authors:  Eric K Patterson; Gediminas Cepinskas; Douglas D Fraser
Journal:  Front Med (Lausanne)       Date:  2022-07-08

8.  More than a biomarker: the systemic consequences of heparan sulfate fragments released during endothelial surface layer degradation (2017 Grover Conference Series).

Authors:  Kaori Oshima; Sarah M Haeger; Joseph A Hippensteel; Paco S Herson; Eric P Schmidt
Journal:  Pulm Circ       Date:  2018 Jan-Mar       Impact factor: 3.017

9.  Indoor nanoscale particulate matter-induced coagulation abnormality based on a human 3D microvascular model on a microfluidic chip.

Authors:  Yan Li; Chuanlin Hu; Pengcheng Wang; Yan Liu; Luyang Wang; Qingmeng Pi; Zhiyong Gong; Xu Yang; Michael Mak; Yang Wu
Journal:  J Nanobiotechnology       Date:  2019-02-01       Impact factor: 10.435
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.